Patient P-02420
Therapy response
Declining
Tolerance
Deteriorating
GI state
Stable
Inflammatory state
Favorable
Nutritional resilience
Declining
Discontinuation risk
30%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S15
- Day 159 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 159.
Primary contributors, last 14 days
- Toxicity+14
- Treatment adherence+9
- Nutritional resilience-6
- Inflammatory activity-2
What helped?
No interventions yet.
LIFE OS recommendation
Dosing / Timing Recommendation DT-01
51%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 75% showed improvement
- median effect visible after 5 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable64 min
worsening · -5.4 vs previous 14 d
Sleep duration
Wearable6.3 h
stable · -0.0 vs previous 14 d
Energy level
Daily log4.5/10
stable · -0.2 vs previous 14 d
Steps
Wearable7,495
worsening · -779 vs previous 14 d
GI burden
Companion45.9/100
worsening · +7.8 vs previous 14 d
Adherence
Companion97.2 %
stable · -0.5 vs previous 14 d
Sleep quality
Wearable32.3/100
worsening · -4.2 vs previous 14 d
Glucose, CGM daily mean
CGM134 mg/dL
stable · +1.4 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 48 from the failing basin, 41 from restoration.
Would help
Would not help
- Nothing clearly counter-productive in the record.
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-5.9supporter · 95%
- Simple carbohydrates-3supporter · 67%
- Caffeine-2.8supporter · 57%
- Alcohol+1.9no signal · 39%
- Ultra-processed food-1.3no signal · 20%
- Histamine load+1no signal · 16%
- Insoluble fibre-0.2no signal · 15%
- Dietary fat load-0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓20
- Daily logGI symptom score 46 and rising
- Butyrate / short-chain fatty acid production ↓20
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↓20
- WearableShort sleep window
- Inflammatory signalling ↓15
- WearableHRV 31 ms, trending down
DNA
Fictional pharmacogenomic panel
- CYP2D6 Normal metabolizerExpected exposure
- GLP1R rs6923761 AAltered receptor sensitivity
Microbiome
Shannon diversity 3 · butyrate capacity 55/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 34 ms
- Sleep
- 6.5 h
- Steps
- 8,282
- Resting HR
- 72 bpm
Daily log: GI score 46, nutritional resilience 50, adherence 97.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02093 | 30% | S05 | AD-05 | no change | 40 |
| P-02483 | 39% | S06 | BR-03 | no change | 64 |
| P-02087 | 32% | S01 | BR-03 | no change | 40 |
| P-02280 | 31% | S07 | BR-03 | no change | 50 |
| P-02267 | 30% | S09 | BR-03 | no change | 45 |
| P-02354 | 35% | S01 | CR-01 | improved | 78 |
| P-02233 | 29% | S16 | CR-01 | improved | 66 |
| P-02491 | 41% | S09 | DT-01 | no change | 65 |
| P-02274 | 38% | S15 | DT-01 | improved | 50 |
| P-02235 | 36% | S14 | DT-01 | improved | 50 |
| P-02339 | 35% | S03 | DT-01 | improved | 50 |
| P-02395 | 35% | S12 | DT-01 | improved | 57 |